Please login to the form below

Not currently logged in
Email:
Password:

BCMA-targeting therapy

This page shows the latest BCMA-targeting therapy news and features for those working in and with pharma, biotech and healthcare.

FDA grants orphan drug status to Allogene’s BCMA-targeted treatment for multiple myeloma

FDA grants orphan drug status to Allogene’s BCMA-targeted treatment for multiple myeloma

ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies. ... Phase 1 data from the ALLO-715 UNIVERSAL trial demonstrated for the first time that

Latest news

  • BMS and bluebird bio gain FDA approval for multiple myeloma therapy BMS and bluebird bio gain FDA approval for multiple myeloma therapy

    Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s BCMA-targeting CAR T cell therapy Abecma – previously known as ide-cel

  • bluebird bio to separate oncology and rare diseases units bluebird bio to separate oncology and rare diseases units

    Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will

  • Bluebird bio leans on pipeline and Zynteglo launch as revenues fall Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

    Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma. ... Aside from the mixed figures, bluebird is looking forward and focusing on the

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    or whose disease has relapsed,” said Stanley Frankel, senior vice president, cellular therapy development, BMS. ... In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for

  • J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

    Both candidates are being studied in multiple myeloma. Johnson and Johnson and Bristol-Myers Squibb/Bluebird bio have both revealed data from their respective BCMA-targeting CAR-T therapies in multiple ... BMS/Bluebird also had their own CAR-T data in

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...